https://investigoxvos.roche.com.ar2026-03-24https://investigoxvos.roche.com.ar/es/trials.html2025-06-06https://investigoxvos.roche.com.ar/es/trials/uncategorized.html2023-09-12https://investigoxvos.roche.com.ar/es/trials/cancer/bc/a-study-of-the-efficacy-and-safety-of-atezolizumab-plus-chemothe.html2025-08-29https://investigoxvos.roche.com.ar/es/trials/cancer/bc/a-study-of-trastuzumab-emtansine-versus-trastuzumab-as-adjuvant-.html2025-06-20https://investigoxvos.roche.com.ar/es/trials/cancer/bc/a-study-evaluating-the-efficacy-and-safety-of-gdc-0077--75564.html2025-08-14https://investigoxvos.roche.com.ar/es/trials/cancer/bc/a-study-evaluating-the-efficacy-and-safety-of-gdc-9545--37336.html2025-07-03https://investigoxvos.roche.com.ar/es/trials/cancer/bc/a-study-evaluating-the-efficacy-and-safety-of-inavolisi-04316.html2025-06-20https://investigoxvos.roche.com.ar/es/trials/cancer/bc/a-study-of-ro7247669---nab-paclitaxel-compared-with-pem-15706.html2025-06-20https://investigoxvos.roche.com.ar/es/trials/cancer/bc/a-study-to-evaluate-efficacy-and-safety-of-giredestrant-50902.html2025-06-20https://investigoxvos.roche.com.ar/es/trials/cancer/bc/a-study-of-atezolizumab--tecentriq--plus-nab-paclitaxel-22823.html2025-07-08https://investigoxvos.roche.com.ar/es/trials/cancer/bc/a-study-of-pertuzumab-in-addition-to-chemotherapy-and-t-28091.html2025-08-28https://investigoxvos.roche.com.ar/es/trials/cancer/lung-cancer/a-study-to-evaluate-efficacy-and-safety-of-multiple-targeted-the.html2025-08-28https://investigoxvos.roche.com.ar/es/trials/cancer/lung-cancer/a-study-to-evaluate-participant-and-healthcare-professi-70557.html2025-08-15https://investigoxvos.roche.com.ar/es/trials/cancer/lung-cancer/a-study-evaluating-the-safety--activity--and-pharmacoki-06656.html2025-08-15https://investigoxvos.roche.com.ar/es/trials/cancer/lung-cancer/a-study-of-tiragolumab-plus-atezolizumab-compared-with--98034.html2025-06-20https://investigoxvos.roche.com.ar/es/trials/cancer/fmi.html2024-11-13https://investigoxvos.roche.com.ar/es/trials/cancer/non-hodgkins-lymphoma/an-open-label-study-comparing-glofitamab-and-polatuzuma-51322.html2025-06-20https://investigoxvos.roche.com.ar/es/trials/cancer/lung-cancer-test.html2023-09-12https://investigoxvos.roche.com.ar/es/trials/cancer/lung-cancer-test2.html2023-09-12https://investigoxvos.roche.com.ar/es/trials/autoimmune-disorder/crohn-s-disease/a-study-to-assess-the-efficacy-and-safety-of-induction--32899.html2025-08-12https://investigoxvos.roche.com.ar/es/trials/autoimmune-disorder/crohn-s-disease/a-study-to-assess-the-efficacy-and-safety-of-induction--94939.html2025-08-15https://investigoxvos.roche.com.ar/es/trials/autoimmune-disorder/sle/a-study-to-evaluate-the-efficacy-and-safety-of-obinutuz-62318.html2025-06-20https://investigoxvos.roche.com.ar/es/trials/autoimmune-disorder/ibd/a-study-to-assess-the-efficacy-and-safety-of-ro7790121--09855.html2026-03-02https://investigoxvos.roche.com.ar/es/trials/autoimmune-disorder/ln/a-study-to-evaluate-the-efficacy-and-safety-of-obinutuz-33293.html2025-09-18https://investigoxvos.roche.com.ar/es/trials/autoimmune-disorder/myasthenia-gravis-iab/myasthenia-gravis--mg--disease-information-.html2023-09-12https://investigoxvos.roche.com.ar/es/trials/autoimmune-disorder/neuromyelitis-optica.html2023-09-12https://investigoxvos.roche.com.ar/es/trials/autoimmune-disorder/multiple-sclerosis/a-pharmacokinetics--pk---pharmacodynamics--pd---safety--83549.html2026-01-15https://investigoxvos.roche.com.ar/es/trials/autoimmune-disorder/multiple-sclerosis/a-study-to-assess-bioequivalence-of-two-subcutaneous--s-18385.html2026-02-13https://investigoxvos.roche.com.ar/es/trials/eye-disorder/dme/a-study-to-investigate-ro7200220-in-combination-with-ra-51781.html2025-10-15https://investigoxvos.roche.com.ar/es/trials/eye-disorder/amd/a-study-of-the-efficacy--safety--and-pharmacokinetics-o-88020.html2025-06-20https://investigoxvos.roche.com.ar/es/trials/neurodegenerative-disorder/ad/safety-and-efficacy-study-of-gantenerumab-in-participants-with-e.html2024-06-22https://investigoxvos.roche.com.ar/es/trials/neurodegenerative-disorder/ad/a-study-to-evaluate-the-safety-and-tolerability-of-long-88018.html2024-08-31https://investigoxvos.roche.com.ar/es/trials/neurodegenerative-disorder/ad/a-study-to-evaluate-the-safety--tolerability--and-effic-66535.html2024-08-31https://investigoxvos.roche.com.ar/es/trials/neurodegenerative-disorder/hd/a-study-to-evaluate-the-safety--biomarkers--and-efficac-41200.html2025-08-29https://investigoxvos.roche.com.ar/es/trials/neurodegenerative-disorder/hd/frequency-of-selected-single-nucleotide-polymorphisms-i-91631.html2025-08-15https://investigoxvos.roche.com.ar/es/trials/metabolic-disorder/lysosomal-storage-diseases.html2023-09-12https://investigoxvos.roche.com.ar/es/faq.html2023-10-19https://investigoxvos.roche.com.ar/es/faq/what-is-a-clinical-trial.html2024-11-12https://investigoxvos.roche.com.ar/es/faq/why-should-i-consider-taking-part-in-a-clinical-trial.html2024-11-12https://investigoxvos.roche.com.ar/es/faq/roche-in-clinical-trials.html2024-11-12https://investigoxvos.roche.com.ar/es/faq/what-is-a-clinical-trial1.html2024-11-12https://investigoxvos.roche.com.ar/es/faq/advancing-inclusive-research.html2023-10-19https://investigoxvos.roche.com.ar/es/faq/what-is-an-observational-trial.html2023-10-19https://investigoxvos.roche.com.ar/es/glossary-terms.html2023-11-08https://investigoxvos.roche.com.ar/es/a-note-about-covid-19.html2023-10-19https://investigoxvos.roche.com.ar/es/About.html2024-05-06https://investigoxvos.roche.com.ar/es/disease-area-overview.html2024-07-26https://investigoxvos.roche.com.ar/es/solr-search.html2023-11-06https://investigoxvos.roche.com.ar/es/new-solr-search.html2024-02-19